{"content":"<li class=\"n-box-item date-title\" data-end=\"1490414399\" data-start=\"1490328000\" data-txt=\"Sunday, December 22, 2019\">Friday, March 24, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3253425\" data-ts=\"1490391513\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253425-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/WFT' title='Weatherford International Ltd.'>WFT</a> <font color='green'>+7.8%</font>. <a href='https://seekingalpha.com/symbol/FUEL' title='Rocket Fuel'>FUEL</a> <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/XENE' title='Xenon Pharmaceuticals'>XENE</a> <font color='green'>+3.3%</font>. <a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies'>MIK</a> <font color='green'>+2.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/WING' title='Wingstop, Inc.'>WING</a> <font color='red'>-3.0%</font>. <a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a> <font color='red'>-1.7%</font>. <a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a> <font color='red'>-1.7%</font>. <a href='https://seekingalpha.com/symbol/OPHT' title='Ophthotech Corporation'>OPHT</a> <font color='red'>-1.6%</font>. <a href='https://seekingalpha.com/symbol/AAV-OLD' title='Advantage Oil & Gas Ltd.'>AAV-OLD</a> <font color='red'>-1.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253425\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$WFTIQ $FUEL $PDLI - After Hours Gainers / Losers https://seekingalpha.com/news/3253425-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3253425-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253421\" data-ts=\"1490388323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253421-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='green'>+6.1%</font>. <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a> <font color='green'>+5.1%</font>. <a href='https://seekingalpha.com/symbol/PSLV' title='Sprott Physical Silver Trust'>PSLV</a> <font color='green'>+2.3%</font>. <a href='https://seekingalpha.com/symbol/SLV' title='iShares Silver Trust ETF'>SLV</a> <font color='green'>+2.1%</font>. <a href='https://seekingalpha.com/symbol/SIVR' title='ETFS Physical Silver Trust ETF'>SIVR</a> <font color='green'>+2.1%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a> <font color='red'>-7.9%</font>. <a href='https://seekingalpha.com/symbol/TAN' title='Guggenheim Solar ETF'>TAN</a> <font color='red'>-3.7%</font>. <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> <font color='red'>-3.7%</font>. <a href='https://seekingalpha.com/symbol/REMX' title='VanEck Vectors Rare Earth/Strategic Metals ETF'>REMX</a> <font color='red'>-3.4%</font>. <a href='https://seekingalpha.com/symbol/IJS' title='iShares S&P Small-Cap 600 Value ETF'>IJS</a> <font color='red'>-3.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253421\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$VXX $UNG $PSLV - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3253421-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3253421-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253413\" data-ts=\"1490385846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THC\" target=\"_blank\">THC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253413-hospitals-rally-on-republican-backpedal-on-health-bill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hospitals rally on Republican backpedal on health bill</a></h4><ul><li>Consistent with recent movement, hospital operators jump on the news that Republicans have postponed the vote on the American Health Care Act.</li><li>(<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+7.5%</font>)(<a href='https://seekingalpha.com/symbol/ACHC' title='Acadia Healthcare Co.'>ACHC</a> <font color='green'>+5.9%</font>)(<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='green'>+9.8%</font>)(<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a> <font color='green'>+3.4%</font>)(<a href='https://seekingalpha.com/symbol/LPNT' title='LifePoint Health, Inc.'>LPNT</a> <font color='green'>+3.6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253413\" data-linked=\"Hospitals rally on Republican backpedal on health bill\" data-tweet=\"$THC $THC $ACHC - Hospitals rally on Republican backpedal on health bill https://seekingalpha.com/news/3253413-hospitals-rally-on-republican-backpedal-on-health-bill?source=tweet\" data-url=\"https://seekingalpha.com/news/3253413-hospitals-rally-on-republican-backpedal-on-health-bill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253409\" data-ts=\"1490385261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOS\" target=\"_blank\">KOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253409-kosmos-energy-starts-phase-two-exploration-drilling-off-western-africa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kosmos Energy starts phase two exploration drilling off western Africa</a></h4><ul>     <li>Kosmos Energy (<a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy'>KOS</a> <font color='green'>+3.9%</font>) maintains strong gains after announcing the <a href=\"https://seekingalpha.com/pr/16780374-kosmos-energy-begins-second-phase-exploration-drilling-program-offshore-mauritania-senegal\" target=\"_blank\">start of the second phase</a> of its multi-well exploration drilling program offshore of Mauritania and Senegal in western Africa.</li>     <li>The <em>Atwood Achiever</em>, an ultra-deepwater drillship on lease from Atwood Oceanics (<a href='https://seekingalpha.com/symbol/ATW' title='Atwood Oceanics Inc.'>ATW</a> <font color='green'>+0.3%</font>), has launched operations on the first exploration well in the Yakaar prospect west of the company's earlier Teranga discovery.</li><li>KOS is <a href=\"https://seekingalpha.com/news/3231339-bp-strikes-deal-kosmos-west-africa-offshore-gas-stake-916m\" target=\"_blank\">partnering</a> with <a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a> in the area, where the companies plan  three exploration wells for this year leading to a new liquefied natural gas hub.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253409\" data-linked=\"Kosmos Energy starts phase two exploration drilling off western Africa\" data-tweet=\"$KOS $KOS $ATW - Kosmos Energy starts phase two exploration drilling off western Africa https://seekingalpha.com/news/3253409-kosmos-energy-starts-phase-two-exploration-drilling-off-western-africa?source=tweet\" data-url=\"https://seekingalpha.com/news/3253409-kosmos-energy-starts-phase-two-exploration-drilling-off-western-africa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253408\" data-ts=\"1490384792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HGEN\" target=\"_blank\">HGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253408-kalobios-raises-additional-5_5m-via-debt-financing-shares-slip-23\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KaloBios raises additional $5.5M via debt financing; shares slip 23%</a></h4><ul><li>Pink sheet stock KaloBios (KBIO <font color='red'>-23.3%</font>) drops on increased volume, albeit on turnover of only 12,350 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16780087-kalobios-receives-5_5m-new-financing-existing-investors\" target=\"_blank\">announcement </a>that it has raised an additional $5.5M from existing investors via an amendment to its term loan facility. The total principal amount of the loan is now $9.2M.</li><li>Proceeds will fund working capital.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253408\" data-linked=\"KaloBios raises additional $5.5M via debt financing; shares slip 23%\" data-tweet=\"$HGEN - KaloBios raises additional $5.5M via debt financing; shares slip 23% https://seekingalpha.com/news/3253408-kalobios-raises-additional-5_5m-via-debt-financing-shares-slip-23?source=tweet\" data-url=\"https://seekingalpha.com/news/3253408-kalobios-raises-additional-5_5m-via-debt-financing-shares-slip-23\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253407\" data-ts=\"1490384566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANDV\" target=\"_blank\">ANDV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253407-tesoro-four-refiners-downgraded-credit-suisse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesoro, four other refiners downgraded at Credit Suisse</a></h4><ul>     <li>Tesoro (TSO <font color='red'>-1.5%</font>) is lower after Credit Suisse <a href=\"http://thefly.com/landingPageNews.php?id=2524995&amp;headline=AAPL;GME;TSO;ETR;ROP-On-The-Fly-Top-five-analyst-downgrades-\" target=\"_blank\">downgrades</a> shares to Neutral from Outperform with a $93 price target, cut from $110, one of <a href=\"https://www.streetinsider.com/Analyst+Comments/Credit+Suisse+Downgrades+5+US+Refiners/12702952.html\" target=\"_blank\">five refiners the firm downgrades</a> as it says it does not want to chase relative valuation as refiners rebalance.</li>     <li>TheFly.com reports that Credit Suisse's longer term view of broader refining margins remains relatively muted, and TSO's business has a \"more negative grey sky sensitivity\" than some peers given higher California operational costs and a greater share of R&amp;M income, despite progress on diversification and retail integration.</li>     <li>The firm also cuts Alon USA Energy (<a href='https://seekingalpha.com/symbol/ALJ' title='Alon USA Energy, Inc.'>ALJ</a> <font color='red'>-3.5%</font>), Delek US Holdings (<a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a> <font color='red'>-3.6%</font>), Western Refining (<a href='https://seekingalpha.com/symbol/WNR' title='Western Refining, Inc.'>WNR</a> <font color='red'>-1.3%</font>) to Neutral from Outperform, and drops Calumet Specialty Products (<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='red'>-1.3%</font>) to Underperform from Neutral.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253407\" data-linked=\"Tesoro, four other refiners downgraded at Credit Suisse\" data-tweet=\"$ANDV $ANDV $ALJ - Tesoro, four other refiners downgraded at Credit Suisse https://seekingalpha.com/news/3253407-tesoro-four-refiners-downgraded-credit-suisse?source=tweet\" data-url=\"https://seekingalpha.com/news/3253407-tesoro-four-refiners-downgraded-credit-suisse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253403\" data-ts=\"1490382450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PNRA\" target=\"_blank\">PNRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253403-panera-bread-clears-250-for-first-time\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Panera Bread clears $250 for first time</a></h4><ul><li>Shares of Panera Bread (<a href='https://seekingalpha.com/symbol/PNRA' title='Panera Bread Company'>PNRA</a> <font color='green'>+1.1%</font>) traded over $250 for the first time earlier today.</li><li>The restaurant stock is now about 8% short of the Street high price target of $270 set by both Cowen and Telsey Advisory. Panera trades at about 32.5X its 2017 earnings per share guidance.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3241281-panera-aims-high-profit-guidance-delivery-target\" target=\"_blank\">Panera aims high with profit guidance and delivery target</a> (Feb. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253403\" data-linked=\"Panera Bread clears $250 for first time\" data-tweet=\"$PNRA - Panera Bread clears $250 for first time https://seekingalpha.com/news/3253403-panera-bread-clears-250-for-first-time?source=tweet\" data-url=\"https://seekingalpha.com/news/3253403-panera-bread-clears-250-for-first-time\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253399\" data-ts=\"1490382037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253399-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FSNN' title='Fusion Connect, Inc.'>FSNN</a> <font color='green'>+19%</font>. COGT <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/BCOV' title='Brightcove'>BCOV</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/VLTC' title='Voltari Corporation'>OTC:VLTC</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ISNS' title='Image Sensing Systems, Inc.'>ISNS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group'>VNET</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/IDSY' title='I.D. Systems, Inc.'>IDSY</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253399\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$FSNN $FLNT $QUIK - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3253399-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3253399-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253400\" data-ts=\"1490381783\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGHEF\" target=\"_blank\">PGHEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253400-pengrowth-energy-to-sell-bernadet-montney-lands-for-c-92m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pengrowth Energy to sell Bernadet Montney lands for C$92M</a></h4><ul><li>Pengrowth Energy (PGH <font color='green'>+1.9%</font>) after announcing last night that it <a href=\"https://seekingalpha.com/pr/16780233-pengrowth-announces-sale-bernadet-montney-lands-92-million\" target=\"_blank\">agrees to sell</a> its non-producing Montney lands at Bernadet in British Columbia to an undisclosed buyer for C$92M (US$68.8M).</li><li>PGH says the land has no associated production, cash flow and neither reserves or  resources assigned to it in its year-end 2016 reserves report.</li><li>The Montney deal follows its C$180M sale of non-core assets in the Swan Hills area <a href=\"https://seekingalpha.com/news/3252180-pengrowth-energy-sell-swan-hills-properties-180m\" target=\"_blank\">earlier this week</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253400\" data-linked=\"Pengrowth Energy to sell Bernadet Montney lands for C$92M\" data-tweet=\"$PGHEF - Pengrowth Energy to sell Bernadet Montney lands for C$92M https://seekingalpha.com/news/3253400-pengrowth-energy-to-sell-bernadet-montney-lands-for-c-92m?source=tweet\" data-url=\"https://seekingalpha.com/news/3253400-pengrowth-energy-to-sell-bernadet-montney-lands-for-c-92m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253392\" data-ts=\"1490379957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDP\" target=\"_blank\">MDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253392-time-getting-closer-to-sale-north-of-20-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Time getting closer to sale north of $20 - Bloomberg</a></h4><ul><li>A sale of the entire company is more likely than not, and a deal valuing the publisher at more than $20 per share could be reached as early as next week, according to the report.</li><li>Meredith (<a href='https://seekingalpha.com/symbol/MDP' title='Meredith Corporation'>MDP</a> <font color='green'>+1%</font>) and a group including Pamplona Capital remain in the running, as are at least two other suitors, including a publicly traded company.</li><li>TIME&nbsp;<font color='green'>+0.8%</font>&nbsp;to $19.40</li><li>Previously: <a href=\"https://seekingalpha.com/news/3251987-ny-post-meredith-may-front-runner-acquire-time\" target=\"_blank\">NY Post: Meredith may be front-runner to acquire Time</a> (March 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253392\" data-linked=\"Time getting closer to sale north of $20 - Bloomberg\" data-tweet=\"$MDP - Time getting closer to sale north of $20 - Bloomberg https://seekingalpha.com/news/3253392-time-getting-closer-to-sale-north-of-20-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3253392-time-getting-closer-to-sale-north-of-20-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253389\" data-ts=\"1490378633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253389-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/AXU' title='Alexco Resource Corporation'>AXU</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SXC' title='SunCoke Energy'>SXC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/KLDX' title='Klondex Mines Ltd.'>KLDX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SXCP' title='SunCoke Energy Partners'>SXCP</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/GSV' title='Gold Standard Ventures'>GSV</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253389\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$GBR $ERN $ECR-OLD - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3253389-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3253389-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253385\" data-ts=\"1490376180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASPS\" target=\"_blank\">ASPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253385-shorts-press-bets-in-altisource-portfolio-solutions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shorts press bets in Altisource Portfolio Solutions</a></h4><ul><li><a href=\"https://www.shortside.com/authentication/login/default.aspx\" target=\"_blank\">According to shortside.com</a>, shorts have been selling into the continuing rally in Altisource Portfolio Solutions (<a href='https://seekingalpha.com/symbol/ASPS' title='Altisource Portfolio Solutions SA'>ASPS</a> <font color='green'>+3%</font>), with a record 5.72M shares shorted as of yesterday - this as soaring borrowing rates (over 70%) suggest there's less and less available shares out there.</li><li>The stock has now regained nearly all of its mid-February, near-30%, post-earnings plunge.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252825-short-squeeze-building-altisource-portfolio-solutions\" target=\"_blank\">Short squeeze building in Altisource Portfolio Solutions?</a> (March 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253385\" data-linked=\"Shorts press bets in Altisource Portfolio Solutions\" data-tweet=\"$ASPS - Shorts press bets in Altisource Portfolio Solutions https://seekingalpha.com/news/3253385-shorts-press-bets-in-altisource-portfolio-solutions?source=tweet\" data-url=\"https://seekingalpha.com/news/3253385-shorts-press-bets-in-altisource-portfolio-solutions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253381\" data-ts=\"1490375450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALR\" target=\"_blank\">ALR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253381-alere-up-3-investors-anticipate-improved-prospects-for-favorable-outcome-abbott-based-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alere up 3% as investors anticipate improved prospects for favorable outcome with Abbott based on ruling by judge in different case</a></h4><ul><li>Money flow perks up in Alere (<a href='https://seekingalpha.com/symbol/ALR' title='Alere Inc.'>ALR</a> <font color='green'>+2.5%</font>) on apparent increased optimism from investors that its squabble with would-be acquirer Abbott (<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a> <font color='green'>+0.1%</font>) may end favorably.</li><li>Judge Leo Strine recently dissented (4-1)in a case involving a botched merger between Williams Co. and Energy Transfer Equity, saying the companies could have easily saved the combination by making a \"modest amendment.\" The situation appears similar to the ABT/ALR dispute. Judge Sam Glasscock, who voted with the majority, is handling both cases.</li><li>Widener University professor and specialist in Delaware corporate law Larry Hamermesh doesn't see much carryover though, calling it a \"stretch\" to draw a conclusion from the Williams decision since the two cases and the related legal issues are different.</li><li>Abbott has been trying to back out of the $5.8B deal citing a \"substantial loss in value\" due to a range of problems at Alere.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3253381\" data-linked=\"Alere up 3% as investors anticipate improved prospects for favorable outcome with Abbott based on ruling by judge in different case\" data-tweet=\"$ALR $ALR $ABT - Alere up 3% as investors anticipate improved prospects for favorable outcome with Abbott based on ruling by judge in different case https://seekingalpha.com/news/3253381-alere-up-3-investors-anticipate-improved-prospects-for-favorable-outcome-abbott-based-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3253381-alere-up-3-investors-anticipate-improved-prospects-for-favorable-outcome-abbott-based-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253378\" data-ts=\"1490374693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMY\" target=\"_blank\">HMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253378-harmony-gold-says-strike-ends-south-africa-mine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harmony Gold says strike ends at South Africa mine</a></h4><ul>     <li>Harmony Gold (<a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+3.6%</font>) says the <a href=\"http://www.miningmx.com/top-story/29299-amcu-calls-strike-harmony-golds-kusasalethu-mine/\" target=\"_blank\">strike is over</a> at its Kusasalethu mine in South Africa after losing 3-4 days of full production.</li><li>HMY says the  strike was ended following discussions between its senior  management and the leadership of the AMCU union.</li><li>The mine produces ~13% of HMY&rsquo;s total 1M-1.1M oz./year in production and generates 10% of the company's total cash  flow.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253378\" data-linked=\"Harmony Gold says strike ends at South Africa mine\" data-tweet=\"$HMY - Harmony Gold says strike ends at South Africa mine https://seekingalpha.com/news/3253378-harmony-gold-says-strike-ends-south-africa-mine?source=tweet\" data-url=\"https://seekingalpha.com/news/3253378-harmony-gold-says-strike-ends-south-africa-mine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253376\" data-ts=\"1490374197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253376-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+204%</font>. <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='green'>+44%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/VLTC' title='Voltari Corporation'>OTC:VLTC</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+18%</font>. COGT <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/BCOV' title='Brightcove'>BCOV</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/FUEL' title='Rocket Fuel'>FUEL</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/XENE' title='Xenon Pharmaceuticals'>XENE</a> <font color='red'>-53%</font>. <a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/ROSG-OLD' title='Rosetta Genomics Ltd.'>ROSG-OLD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a> <font color='red'>-10%</font>. ITUS <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/USCR' title='US Concrete Inc.'>USCR</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253376\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$HTGM $ZAIS $GBR - Midday Gainers / Losers https://seekingalpha.com/news/3253376-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3253376-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253370\" data-ts=\"1490371456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253370-finish-line-margins-hit-promotions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finish Line margins hit by promotions</a></h4><ul><li>FInish Line (NASDAQ:<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a>) struggled to sell its products in Q4, leading to a margin-walloping increase in promotions to clear inventory.</li><li>Although management points to the clean inventory sheet, Susquehanna warns that it's clear that the company is losing more market share to Foot Locker (<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a> <font color='green'>+0.1%</font>) due in part to the product assortment.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253270-finish-line-misses-0_21-beats-revenue\" target=\"_blank\">Finish Line misses by $0.21, beats on revenue</a> (March 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253274-finish-line-lower-post-fq4-results\" target=\"_blank\">Finish Line lower post FQ4 results</a> (March 24)</li><li>FINL is&nbsp;<font color='red'>down 16.44%</font>&nbsp;and traded as low as $12.63.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253370\" data-linked=\"Finish Line margins hit by promotions\" data-tweet=\"$FINL $FINL $FL - Finish Line margins hit by promotions https://seekingalpha.com/news/3253370-finish-line-margins-hit-promotions?source=tweet\" data-url=\"https://seekingalpha.com/news/3253370-finish-line-margins-hit-promotions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253369\" data-ts=\"1490371323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253369-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>    <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253369\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SNAK $VNCE $SPWH - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3253369-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3253369-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253366\" data-ts=\"1490370637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGLS\" target=\"_blank\">RGLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253366-regulus-perks-up-20-on-chairmans-stock-purchase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regulus perks up 20% on Chairman&#39;s stock purchase</a></h4><ul><li>Nano cap Regulus Therapeutics (<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+20%</font>) is up on average volume. The jump in buying is being stoked by the <a href=\"http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=11951321&amp;RcvdDate=3/23/2017&amp;CoName=REGULUS%20THERAPEUTICS%20INC.&amp;FormType=4&amp;View=html\" target=\"_blank\">disclosure </a>that Chairman Stelios Papadopoulos recently acquired a 500K stake at an average price of ~$1.22.</li><li>The company's pipeline consists of HCV candidate RG-101, Alport syndrome candidate RG-012, diabetes candidate RG-125 and kidney disease candidate RGLS4326.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253366\" data-linked=\"Regulus perks up 20% on Chairman&#39;s stock purchase\" data-tweet=\"$RGLS - Regulus perks up 20% on Chairman&#39;s stock purchase https://seekingalpha.com/news/3253366-regulus-perks-up-20-on-chairmans-stock-purchase?source=tweet\" data-url=\"https://seekingalpha.com/news/3253366-regulus-perks-up-20-on-chairmans-stock-purchase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253367\" data-ts=\"1490370598\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USCR\" target=\"_blank\">USCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253367-u-s-concreteminus-10-suntrust-out-defending-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Concrete -10%; SunTrust out defending the stock</a></h4><ul>     <li>U.S. Concrete (<a href='https://seekingalpha.com/symbol/USCR' title='US Concrete Inc.'>USCR</a> <font color='red'>-10.4%</font>) plunges 10% following <a href=\"https://seekingalpha.com/news/3253319-u-s-concrete-cfo-tusa-resign\" target=\"_blank\">this morning's news</a> of the CFO's resignation and a sudden change in auditors, but TheFly.com reports SunTrust says <a href=\"http://thefly.com/landingPageNews.php?id=2524982&amp;headline=USCR-US-Concrete-should-be-bought-on-todays-selloff-says-SunTrust\" target=\"_blank\">shares should be bought</a> on today's selloff.</li><li>Analyst Rohit Seth says that while the optics look bad, he confirmed with the company that the auditor change to Ernst &amp; Young from Grant Thornton is  unrelated to the CFO resignation.</li>     <li>Seth believes USCR's growth prospects remain intact, and recommends using  today's weakness as a buying opportunity; the firm has a Buy rating and $90 price target on the shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253367\" data-linked=\"U.S. Concrete -10%; SunTrust out defending the stock\" data-tweet=\"$USCR - U.S. Concrete -10%; SunTrust out defending the stock https://seekingalpha.com/news/3253367-u-s-concreteminus-10-suntrust-out-defending-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3253367-u-s-concreteminus-10-suntrust-out-defending-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253361\" data-ts=\"1490369031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXCM\" target=\"_blank\">DXCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253361-medicare-clarifies-criteria-for-coverage-of-dexcoms-g5-cgm-system-shares-ahead-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medicare clarifies criteria for coverage of DexCom&#39;s G5 CGM System; shares ahead 9%</a></h4><ul><li>DexCom (<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a> <font color='green'>+9%</font>) perks up on average volume in response to the publication of Medicare's criteria for covering the G5 Continuous Glucose Monitoring &#40;CGM&#41; System, the only CGM device under this particular CMS code.</li><li>Eligible patients will have either Type 1 or Type 2 diabetes requiring multiple daily injections of insulin or the use of a continuous subcutaneous insulin infusion pump, have been using a home blood glucose monitor and performing frequent blood glucose monitoring testing and whose insulin treatment regimen requires frequent adjustment by the patient on the basis of CGM testing results. To qualify for reimbursement under this category, the system must be defined as therapeutic CGM (the G5 is the only current qualifier).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3235140-cms-oks-reimbursement-dexcoms-cgm-system\" target=\"_blank\">CMS OKs reimbursement for DexCom's CGM system</a> (Jan. 13)</li><li>Source: The Fly</li></ul><div class=\"tiny-share-widget\" data-id=\"3253361\" data-linked=\"Medicare clarifies criteria for coverage of DexCom&#39;s G5 CGM System; shares ahead 9%\" data-tweet=\"$DXCM - Medicare clarifies criteria for coverage of DexCom&#39;s G5 CGM System; shares ahead 9% https://seekingalpha.com/news/3253361-medicare-clarifies-criteria-for-coverage-of-dexcoms-g5-cgm-system-shares-ahead-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3253361-medicare-clarifies-criteria-for-coverage-of-dexcoms-g5-cgm-system-shares-ahead-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253358\" data-ts=\"1490368657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYX\" target=\"_blank\">AYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253358-alteryxminus-4_6-in-trading-debut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alteryx -4.6% in trading debut</a></h4><ul><li><a href=\"https://www.alteryx.com/\" target=\"_blank\">Alteryx</a>&nbsp;(NYSE:<a href='https://seekingalpha.com/symbol/AYX' title='Alteryx'>AYX</a>)&nbsp;priced late yesterday for offer at <a href=\"http://www.alteryx.com/press-releases/alteryx-announces-pricing-of-initial-public-offering\" target=\"_blank\">$14 per share</a>. Opening&nbsp;<font color='green'>23% over</font>&nbsp;that level at $17.25, shares have at this point retraced near $16.45.</li><li>Specializing in self-service data analytics, Alteryx (<a href=\"https://www.crunchbase.com/organization/alteryx#/entity\" target=\"_blank\">founded 2010</a>, $163M funding raised pre-IPO) recorded, for the 2016 term,&nbsp;<a href=\"https://www.sec.gov/Archives/edgar/data/1689923/000119312517056475/d282071ds1.htm\" target=\"_blank\">$85.8M in revenues</a>&nbsp;(vs. $53.8M Y/Y), a net loss of $24.3M (vs. $21.5M Y/Y) and an $86M accumulated deficit as of December 2016.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253358\" data-linked=\"Alteryx -4.6% in trading debut\" data-tweet=\"$AYX - Alteryx -4.6% in trading debut https://seekingalpha.com/news/3253358-alteryxminus-4_6-in-trading-debut?source=tweet\" data-url=\"https://seekingalpha.com/news/3253358-alteryxminus-4_6-in-trading-debut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253357\" data-ts=\"1490368436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAK\" target=\"_blank\">SNAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253357-inventure-foods-pops-after-shedding-weight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inventure Foods pops after shedding some weight</a></h4><ul><li>Inventure Foods (<a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='green'>+11.1%</font>) shoots higher after the company announces an asset sale of $23M and tips a shareholder-friendly strategy moving ahead.</li><li>Shares of Inventure are still down 54% for the year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253198-inventure-foods-plus-10-percent-asset-sale\" target=\"_blank\">Inventure Foods +10% after asset sale</a> (March 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253357\" data-linked=\"Inventure Foods pops after shedding some weight\" data-tweet=\"$SNAK - Inventure Foods pops after shedding some weight https://seekingalpha.com/news/3253357-inventure-foods-pops-after-shedding-weight?source=tweet\" data-url=\"https://seekingalpha.com/news/3253357-inventure-foods-pops-after-shedding-weight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253355\" data-ts=\"1490367764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253355-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+179%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics, Inc.'>ATOS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/XENE' title='Xenon Pharmaceuticals'>XENE</a> <font color='red'>-50%</font>. <a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ROSG-OLD' title='Rosetta Genomics Ltd.'>ROSG-OLD</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253355\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$HTGM $RGLS $ATOS - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3253355-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3253355-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253351\" data-ts=\"1490366768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/T\" target=\"_blank\">T</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253351-fbr-telecom-media-consolidation-set-to-take-off\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FBR: Telecom/media consolidation set to take off</a></h4><ul>   <li>The Trump administration is set to pave the way for a long-anticipated wave of consolidation in the telecom/media space, FBR says.</li>    <li>Most notably, the $85B combination of AT&amp;T (<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a> <font color='green'>+0.2%</font>) and Time Warner (<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a> <font color='green'>+0.3%</font>) looks set to get its regulatory OK by the end of the year -- that after Trump had actively expressed skepticism about the deal during his presidential campaign and amid a well-covered feud with Time Warner news network CNN.</li>    <li>Analyst Barton Crockett drew other takeaways from a meeting with Michael Lazarus of Telecommunications Law Professionals, Bloomberg notes. Comcast (<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> <font color='green'>+0.8%</font>) may have a tougher time than Charter (<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a> <font color='green'>+1%</font>) when it comes to executing a wireless-company merger, due to its existing concentration of content and pipes.</li>    <li>Meanwhile, while investors in T-Mobile (<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a> <font color='green'>+2.4%</font>) and Sprint (<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a> <font color='green'>+0.7%</font>) look ahead to a possible tie-up, that deal might never happen due to flexible options at T-Mobile. And a reinstatement of the UHF discount by the FCC could clear the way for a combination of Tribune Media (<a href='https://seekingalpha.com/symbol/TRCO' title='Tribune Media Company'>TRCO</a> <font color='green'>+0.4%</font>) and Sinclair Broadcast Group (<a href='https://seekingalpha.com/symbol/SBGI' title='Sinclair Broadcast Group, Inc.'>SBGI</a> <font color='green'>+1%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253351\" data-linked=\"FBR: Telecom/media consolidation set to take off\" data-tweet=\"$T $T $TWX - FBR: Telecom/media consolidation set to take off https://seekingalpha.com/news/3253351-fbr-telecom-media-consolidation-set-to-take-off?source=tweet\" data-url=\"https://seekingalpha.com/news/3253351-fbr-telecom-media-consolidation-set-to-take-off\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>404&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253347\" data-ts=\"1490366184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET\" target=\"_blank\">ET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253347-energy-transfers-exit-from-williams-merger-upheld-court\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy Transfer&#39;s exit from Williams merger upheld by court</a></h4><ul>     <li>Energy Transfer Equity (ETE <font color='green'>+1.7%</font>) <a href=\"https://www.bloomberg.com/news/articles/2017-03-23/court-approves-energy-transfer-s-retreat-from-williams-deal\" target=\"_blank\">had the right to end its merger</a> with Williams Cos. (<a href='https://seekingalpha.com/symbol/WMB' title='Williams Companies Inc'>WMB</a> <font color='green'>+1.2%</font>), the Delaware Supreme Court ruled yesterday,</li>     <li>The ruling means that ETE does not have to fulfill its tie-up with WMB and can press forward with claims that its former takeover target owes a $1.5B breakup fee.</li>     <li>ETE did not violate the 2015 agreement to buy WMB by invoking a tax flaw or allowing buyer&rsquo;s remorse to hinder efforts to rescue the combination, the court ruled.</li>     <li>WMB argues it suffered as much as $10B in damages from ETE&rsquo;s decision to pull out of the deal and rejects ETE's claim that it is owed a breakup fee under the merger agreement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253347\" data-linked=\"Energy Transfer&#39;s exit from Williams merger upheld by court\" data-tweet=\"$ET $ET $WMB - Energy Transfer&#39;s exit from Williams merger upheld by court https://seekingalpha.com/news/3253347-energy-transfers-exit-from-williams-merger-upheld-court?source=tweet\" data-url=\"https://seekingalpha.com/news/3253347-energy-transfers-exit-from-williams-merger-upheld-court\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253343\" data-ts=\"1490365490\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPCO\" target=\"_blank\">TPCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253343-billionaire-chairman-battling-for-control-of-tronc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Billionaire, chairman battling for control of Tronc</a></h4><ul>   <li>A feud over control of Tronc (<a href=\"https://seekingalpha.com/symbol/TRNC\" target=\"_blank\">TRNC</a> <font color='green'>+1.7%</font>) is <a href=\"http://labusinessjournal.com/news/2017/mar/23/what-soon-shiongs-next-step-fight-tronc/\" target=\"_blank\">advancing quickly</a>, as billionaire Patrick Soon-Shiong looks to be moving toward a controlling stake vs. Chairman Michael Ferro, and Oaktree Capital Management getting out of its stake.</li>    <li>Soon-Shiong was moved off Tronc's board and subsequently moved to pay $30M for HG Vora Capital's 5.5% stake. In a filing, the company noted that Oaktree surprisingly moved to <a href=\"https://seekingalpha.com/filing/3472504\" target=\"_blank\">sell its 10.3% stake</a> back to Tronc for $15/share, with the protection of a payout if ownership changed within a year and the new owner paid a premium.</li>    <li>That move is seen as a counter by Ferro to Oaktree's earlier sale of $13.9M worth of shares to Soon-Shiong.</li>    <li>An amendment permits Ferro to buy up to 30% of Tronc's outstanding shares; Soon-Shiong is pressing for the same approval.</li>    <li>Tronc, the former Tribune Publishing, is the parent of the <i>Los Angeles Times,</i> the <i>Chicago Tribune,</i> and several other daily papers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253343\" data-linked=\"Billionaire, chairman battling for control of Tronc\" data-tweet=\"$TPCO - Billionaire, chairman battling for control of Tronc https://seekingalpha.com/news/3253343-billionaire-chairman-battling-for-control-of-tronc?source=tweet\" data-url=\"https://seekingalpha.com/news/3253343-billionaire-chairman-battling-for-control-of-tronc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253340\" data-ts=\"1490364742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGNX\" target=\"_blank\">PGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253340-data-from-mid-stage-study-of-progenics-prostate-cancer-imaging-agent-1404-published-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Data from mid-stage study of Progenics&#39; prostate cancer imaging agent 1404 published in nuclear medicine journal</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16780433-data-phase-2-study-progenics-psma-targeted-imaging-agent-1404-published-journal-nuclear\" target=\"_blank\">Results </a>from a Phase 2 clinical trial evaluating Progenics Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/PGNX' title='Progenics Pharmaceuticals Inc.'>PGNX</a> <font color='green'>+1%</font>) SPECT/CT imaging agent 1404 for visualizing prostate cancer has just been published in the <em>Journal of Nuclear Medicine</em>.</li><li>The data demonstrate the sensitivity of 1404 to detect prostate caner using both visual and semi-quantitative tumor-to-background &#40;TBR&#41; scores.</li><li>The company is currently assessing 1404 in a Phase 3 study in certain patients with low grade prostate cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253340\" data-linked=\"Data from mid-stage study of Progenics&#39; prostate cancer imaging agent 1404 published in nuclear medicine journal\" data-tweet=\"$PGNX - Data from mid-stage study of Progenics&#39; prostate cancer imaging agent 1404 published in nuclear medicine journal https://seekingalpha.com/news/3253340-data-from-mid-stage-study-of-progenics-prostate-cancer-imaging-agent-1404-published-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3253340-data-from-mid-stage-study-of-progenics-prostate-cancer-imaging-agent-1404-published-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253337\" data-ts=\"1490364180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZNH\" target=\"_blank\">ZNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253337-china-southern-higher-again-american-circling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Southern higher again with American circling</a></h4><ul> <li>China Southern (NYSE:<a href='https://seekingalpha.com/symbol/ZNH' title='China Southern Airlines Company Limited'>ZNH</a>) is <font color='green'>up 6.50%</font> on more <a href=\"http://www.straitstimes.com/business/companies-markets/china-southern-in-talks-to-sell-stake-to-american-airlines\" target=\"_blank\">talk</a> that the company is poised to sell a stake to American Airlines Group.</li> <li>Sources tell The Straights Times that the private placement investment will be around $200M.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3253337\" data-linked=\"China Southern higher again with American circling\" data-tweet=\"$ZNH - China Southern higher again with American circling https://seekingalpha.com/news/3253337-china-southern-higher-again-american-circling?source=tweet\" data-url=\"https://seekingalpha.com/news/3253337-china-southern-higher-again-american-circling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253335\" data-ts=\"1490363897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCLP\" target=\"_blank\">HCLP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253335-hi-crush-partnersplus-4-early-after-positive-barrons-article\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hi-Crush Partners +4% early after positive Barron&#39;s article</a></h4><ul>     <li>Hi-Crush Partners (<a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='green'>+4%</font>) opens with impressive gains after <em>Barron's</em> says shares <a href=\"http://www.barrons.com/articles/we-have-a-big-crush-on-this-cheap-energy-play-1490354240\" target=\"_blank\">could climb 50% in a year</a> thanks to rising demand for fracking sand even with far fewer rigs in operation than a few years ago.</li>     <li>HCLP's 20% YTD selloff looks overdone, says Raymond James analyst J. Marshall Adkins, who estimates that 2017 sand volume will reach 60M tons vs. 55M tons in peak 2014 and possibly rising to 90M tons by next year.</li>     <li>For HCLP, it likely would mean a quick rebound in distributable cash flow and the return of investor distributions as soon as later this year, <em>Barron's</em> Jack Hough writes.</li><li>A <em>WSJ</em> article yesterday also noted the <a href=\"https://www.wsj.com/articles/latest-threat-to-u-s-oil-drillers-the-rocketing-price-of-sand-1490266800\" target=\"_blank\">improving market for frac sand</a> and how it is eroding some of the profits energy companies had retained since the end of the oil price bust.</li><li>Also: <a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='green'>+4.2%</font>, <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='green'>+6.3%</font>, <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='green'>+4.5%</font>, <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='green'>+5.9%</font>, <a href='https://seekingalpha.com/symbol/CRR' title='CARBO Ceramics Inc.'>CRR</a> <font color='green'>+3.7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253335\" data-linked=\"Hi-Crush Partners +4% early after positive Barron&#39;s article\" data-tweet=\"$HCLP $HCR $SLCA - Hi-Crush Partners +4% early after positive Barron&#39;s article https://seekingalpha.com/news/3253335-hi-crush-partnersplus-4-early-after-positive-barrons-article?source=tweet\" data-url=\"https://seekingalpha.com/news/3253335-hi-crush-partnersplus-4-early-after-positive-barrons-article\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253333\" data-ts=\"1490363529\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHEN\" target=\"_blank\">SHEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253333-shentel-notes-weakness-in-accounting-controls-tied-to-ntelos-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shentel notes weakness in accounting controls tied to nTelos deal</a></h4><ul>   <li>Shenandoah Telecommunications (<a href='https://seekingalpha.com/symbol/SHEN' title='Shenandoah Telecommunications Co'>SHEN</a> <font color='green'>+2.1%</font>) says in its annual report that it's \"<a href=\"https://seekingalpha.com/filing/3472527\" target=\"_blank\">identified material weaknesses</a>\" in controls over financial reporting, though it expects remediation this year.</li>    <li>The company says it's concluded that \"internal control over financial reporting was ineffective\" as of Dec. 31, related to accounting for \"significant, complex and unusual transactions, accounting for income taxes, and the preparation of the consolidated statements of cash flows.\"</li>    <li>That means primarily last spring's <a href=\"https://seekingalpha.com/news/3173488-shentel-gets-fcc-ok-640m-ntelos-buyout\" target=\"_blank\">acquisition of nTelos</a> and the subsequent asset exchange with Sprint.</li>    <li>It's making changes to address the weaknesses.</li>    <li>Among more standard risks, the company took on substantial additional indebtedness in the nTelos deal, along with nTelos' underfunded defined-benefit pension plan.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253333\" data-linked=\"Shentel notes weakness in accounting controls tied to nTelos deal\" data-tweet=\"$SHEN - Shentel notes weakness in accounting controls tied to nTelos deal https://seekingalpha.com/news/3253333-shentel-notes-weakness-in-accounting-controls-tied-to-ntelos-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3253333-shentel-notes-weakness-in-accounting-controls-tied-to-ntelos-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253327\" data-ts=\"1490362625\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253327-european-advisory-committee-backs-novos-hemophilia-drug-refixia-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory committee backs Novo&#39;s hemophilia drug Refixia; shares ahead 2%</a></h4><ul><li>Novo Nordisk (<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color='green'>+1.9%</font>) follows through on its premarket move stoked by a <a href=\"https://globenewswire.com/news-release/2017/03/24/943924/0/en/Novo-Nordisk-receives-positive-opinion-from-the-European-regulatory-authorities-for-Refixia-nonacog-beta-pegol-N9-GP-for-the-treatment-of-haemophilia-B.html\" target=\"_blank\">positive opinion</a> from the EMA's Committee for Medicinal Products for Human Use &#40;CHMP&#41; recommending approval of Refixia (nonacog beta pegol, N9-GP) for the prophylaxis and on-demand treatment of bleeding in patients with hemophilia B.</li><li>A final decision from the European Commission usually takes ~60 days.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253327\" data-linked=\"European advisory committee backs Novo&#39;s hemophilia drug Refixia; shares ahead 2%\" data-tweet=\"$NVO - European advisory committee backs Novo&#39;s hemophilia drug Refixia; shares ahead 2% https://seekingalpha.com/news/3253327-european-advisory-committee-backs-novos-hemophilia-drug-refixia-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3253327-european-advisory-committee-backs-novos-hemophilia-drug-refixia-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253330\" data-ts=\"1490362549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSG\" target=\"_blank\">TSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253330-amaya-higher-after-ceo-tips-m-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amaya higher after CEO tips M&amp;A interest</a></h4><ul> <li>Amaya (AYA) is open to acquisitions in general, CEO Rafi Ashkenazi tells The Montreal Gazette in an <a href=\"http://montrealgazette.com/business/local-business/pokerstars-owner-amaya-whets-his-appetite-for-risk-by-eyeing-acquisitions\" target=\"_blank\">interview</a>.</li> <li>\"2017 will also be to a large extent the continuing transitional year for us, but probably from the second half of this year, I can be much more focused on finding ways to grow the company, not necessarily organically,\" says Ashkenazi.</li> <li>The company is looking to hire a M&amp;A specialist to focus on a sports betting deal.</li> <li>Shares of Amaya are&nbsp;<font color='green'>up 2.58%</font>&nbsp;in early trading.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253330\" data-linked=\"Amaya higher after CEO tips M&amp;A interest\" data-tweet=\"$TSG - Amaya higher after CEO tips M&amp;A interest https://seekingalpha.com/news/3253330-amaya-higher-after-ceo-tips-m-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3253330-amaya-higher-after-ceo-tips-m-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253326\" data-ts=\"1490362174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253326-gamestop-in-spotlight-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GameStop in the spotlight after earnings</a></h4><ul>     <li>GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) is sized up by Wall Street after reporting holiday sales were ravaged by promotions within the industry. Not a complete surprise, but the company expects to close between 2% and 3% of its stores this year.</li>     <li>Bank of America Merrill Lynch (Neutral): Downgrades the retailer to Neutral from Buy as it considers the weak software lineup for this year. An increase in share buyback activity isn't anticipated.</li>     <li>Wedbush (Outperform, $25 PT): \"We expect shares to trade at a compressed EPS multiple until GameStop slows the decline in its core video game business.\"</li>     <li>Baird (Outperform, $24 PT): Advises that \"long-term/value-oriented\" might be interested in buying on the pullback.</li>     <li>Telsey Advisory (Buy, $24 PT): Notes the FY18 EPS forecast is back-half weighted due to the timing of new software, hardware and iPhone 8 launch.</li>    <li>Macquarie: \"Our concerns for 2017 are primarily with the video game side with GameStop's collectibles and mobile businesses progressing at a solid pace.\"</li>     <li>Sources: <a href=\"http://www.businessinsider.com/gamestop-earnings-stores-closing-2017-3\" target=\"_blank\">Business Insider</a>, Bloomberg and <a href=\"https://www.streetinsider.com/Analyst+Comments/GameStop+%28GME%29%3A+Unhappy+Holidays+-+Wedbush/12703445.html\" target=\"_blank\">StreetInsider</a>.</li>     <li>GameStop is <font color='red'>down 12.15%</font> premarket to $21.05 vs. a 52-week trading range of $20.10 to $33.72.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253326\" data-linked=\"GameStop in the spotlight after earnings\" data-tweet=\"$GME - GameStop in the spotlight after earnings https://seekingalpha.com/news/3253326-gamestop-in-spotlight-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3253326-gamestop-in-spotlight-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253325\" data-ts=\"1490362071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253325-european-advisory-committee-backs-label-update-for-novos-tresiba-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory committee backs label update for Novo&#39;s Tresiba; shares ahead 2% premarket</a></h4><ul><li>The European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; <a href=\"https://www.sec.gov/Archives/edgar/data/353278/000117184317001740/f6k_032417.htm\" target=\"_blank\">adopts a positive opinion</a> recommending the addition of data from the SWITCH 1 and SWITCH 2 clinical trials to the label of Novo Nordisk's (NYSE:<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a>)&nbsp;Tresiba (insulin degludec).</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3223443-novo-nordisk-files-application-europe-include-updated-trial-data-tresiba-label\" target=\"_blank\">Novo Nordisk files application in Europe to include updated trial data in Tresiba label</a> (Nov. 10, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253325\" data-linked=\"European advisory committee backs label update for Novo&#39;s Tresiba; shares ahead 2% premarket\" data-tweet=\"$NVO - European advisory committee backs label update for Novo&#39;s Tresiba; shares ahead 2% premarket https://seekingalpha.com/news/3253325-european-advisory-committee-backs-label-update-for-novos-tresiba-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253325-european-advisory-committee-backs-label-update-for-novos-tresiba-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253321\" data-ts=\"1490361546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGS\" target=\"_blank\">MDGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253321-medigus-prices-equity-offering-shares-down-28-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medigus prices equity offering; shares down 28% premarket</a></h4><ul><li>Ultra-thinly traded nano cap Medigus Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a>) is off&nbsp;<font color='red'>28%</font>&nbsp;premarket on increased volume in response to the <a href=\"https://seekingalpha.com/pr/16780359-medigus-announces-7_5-million-public-offering\" target=\"_blank\">pricing </a>of its best efforts public offering of 979,714 Class A Units at $3.50 and 1,163,144 Class B Units at $3.50.</li><li>Each Class A Unit consists of one American Depositary Share &#40;ADS&#41; and one five-year Series A warrant to purchase one ADS at $3.50.</li><li>Each Class B Unit consists of one pre-funded warrant to purchase one ADS at $0.01 and one Series A warrant.</li><li>Gross proceeds should be ~$7.5M. Net proceeds will be used for general corporate purposes.</li><li>Yesterday's close was $4.41.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253321\" data-linked=\"Medigus prices equity offering; shares down 28% premarket\" data-tweet=\"$MDGS - Medigus prices equity offering; shares down 28% premarket https://seekingalpha.com/news/3253321-medigus-prices-equity-offering-shares-down-28-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253321-medigus-prices-equity-offering-shares-down-28-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253320\" data-ts=\"1490361483\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253320-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/XENE' title='Xenon Pharmaceuticals'>XENE</a> <font color='red'>-47%</font> on XEN801 failing to beat placebo. </li><li><a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='red'>-28%</font> on secondary offering.</li><li><a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='red'>-15%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-13%</font> Q4 earnings miss.</li><li><a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-11%</font> on NYSE notice for delay in 10-K filing.</li><li><a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color='red'>-11%</font> on weak outlook.</li><li><a href='https://seekingalpha.com/symbol/CDOR' title='Condor Hospitality Trust, Inc.'>CDOR</a> <font color='red'>-7%</font> on secondary offering.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253320\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$XENE $MDGS $FINL - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3253320-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3253320-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253318\" data-ts=\"1490361224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253318-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+69%</font>, continues winning streak after receiving CE Mark certification for genetic lung cancer test.</li><li><a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='green'>+60%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+17%</font> on FY earnings.</li><li><a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+15%</font>.</li><li>EBIO <font color='green'>+15%</font> on progress in advancing key pipeline programs.</li><li><a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='green'>+13%</font> on FQ2 earnings.</li><li><a href='https://seekingalpha.com/symbol/SEAS' title='SeaWorld Entertainment Inc.'>SEAS</a> <font color='green'>+13%</font> on 21% stake being sold at $23/share.</li><li><a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a> <font color='green'>+13%</font> on Q4 earnings.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253318\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$HTGM $ZAIS $VSTM - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3253318-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3253318-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253316\" data-ts=\"1490360651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SESN\" target=\"_blank\">SESN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253316-eleven-bio-advancing-pipeline-shares-ahead-15-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eleven Bio advancing pipeline; shares ahead 15% premarket</a></h4><ul><li>Thinly traded nano cap Eleven Biotherapeutics (EBIO) is up&nbsp;<font color='green'>15%</font>&nbsp;premarket on increased volume stoked by <a href=\"https://seekingalpha.com/pr/16780338-eleven-biotherapeutics-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">encouraging progress</a> in advancing key pipeline programs. Management updated investors this morning during its Q4 conference call.</li><li>Enrollment in a pivotal Phase 3 study assessing Vicinium in high-grade non-muscle invasive bladder cancer should be completed in H2 with top-line data expected in 2018.</li><li>A Phase 1/2a study evaluating Proxinium, in combination with a checkpoint inhibitor, in late-stage squamous cell carcinoma of the head and neck will be initiated in H2.</li><li>IND expected to filed next year for systemically-administered TPT, a highly potent, de-immunized plant toxin called deBouganin which may induce an effect against cancer stem cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253316\" data-linked=\"Eleven Bio advancing pipeline; shares ahead 15% premarket\" data-tweet=\"$SESN - Eleven Bio advancing pipeline; shares ahead 15% premarket https://seekingalpha.com/news/3253316-eleven-bio-advancing-pipeline-shares-ahead-15-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253316-eleven-bio-advancing-pipeline-shares-ahead-15-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253319\" data-ts=\"1490360048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USCR\" target=\"_blank\">USCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253319-u-s-concrete-cfo-tusa-to-resign\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Concrete CFO Tusa to resign</a></h4><ul>     <li>U.S. Concrete (NASDAQ:<a href='https://seekingalpha.com/symbol/USCR' title='US Concrete Inc.'>USCR</a>) says CFO Joseph Tusa, Jr., will <a href=\"https://seekingalpha.com/filing/3473243\" target=\"_blank\">resign</a> from the company for \"personal reasons,\" effective July 1.</li><li>Tusa joined USCR in 2015 after spending seven years as CFO of USA&nbsp;Compression GP.</li><li>USCR appoints Kevin Kohutek as its principal accounting officer, effective April 1.</li><li>Also, USCR says it has changed auditors, hiring Ernst &amp; Young as its new independent registered public accounting firm after dismissing Grant Thornton.</li><li>USCR <font color='red'>-2.3%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253319\" data-linked=\"U.S. Concrete CFO Tusa to resign\" data-tweet=\"$USCR - U.S. Concrete CFO Tusa to resign https://seekingalpha.com/news/3253319-u-s-concrete-cfo-tusa-to-resign?source=tweet\" data-url=\"https://seekingalpha.com/news/3253319-u-s-concrete-cfo-tusa-to-resign\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253308\" data-ts=\"1490359867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253308-ptc-therapeutics-withdraws-european-marketing-application-for-translarna-for-cf-shares-ease-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTC Therapeutics withdraws European marketing application for Translarna for CF; shares ease 5% premarket</a></h4><ul><li>PTC Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a>) is down&nbsp;<font color='red'>5%</font>&nbsp;premarket on light volume on the heels of the <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/03/news_detail_002712.jsp&amp;mid=WC0b01ac058004d5c1\" target=\"_blank\">withdrawal </a>of its marketing application in Europe seeking approval of Translarna (ataluren) in cystic fibrosis &#40;CF&#41;. The action was expected after a failed Phase 3 was announced a few weeks ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3248085-ptc-therapeutics-ataluren-flunks-late-stage-cf-study-shares-slump-24-percent-premarket\" target=\"_blank\">PTC Therapeutics' ataluren flunks late-stage CF study; shares slump 24% premarket</a> (March 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253308\" data-linked=\"PTC Therapeutics withdraws European marketing application for Translarna for CF; shares ease 5% premarket\" data-tweet=\"$PTCT - PTC Therapeutics withdraws European marketing application for Translarna for CF; shares ease 5% premarket https://seekingalpha.com/news/3253308-ptc-therapeutics-withdraws-european-marketing-application-for-translarna-for-cf-shares-ease-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3253308-ptc-therapeutics-withdraws-european-marketing-application-for-translarna-for-cf-shares-ease-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253295\" data-ts=\"1490357548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FL\" target=\"_blank\">FL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253295-foot-locker-on-watch-after-weak-finish-line-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foot Locker on watch after weak Finish Line report</a></h4><ul> <li>Shares of Foot Locker (NYSE:<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a>) are&nbsp;<font color='red'>down 1.10%</font>&nbsp;after rival Finish Line reported comparable sales fell 4.5% in FQ4 to miss the consensus estimate.</li> <li>Finish Line expects comparable sales to increase at a low single-digit pace this year.</li> <li>Integer Invesments posted an&nbsp;<a href=\"https://seekingalpha.com/article/4057455-foot-locker-trading-high-still-buy\" target=\"_blank\">article</a>&nbsp;on Foot Locker yesterday. Included was a breakdown of EV/EBITDA ratios in which Foot Locker compared nicely to Nike, Adidas, VF Corp and Finish Line.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3253274-finish-line-lower-post-fq4-results\" target=\"_blank\">Finish Line lower post FQ4 results</a> (March 24)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253295\" data-linked=\"Foot Locker on watch after weak Finish Line report\" data-tweet=\"$FL - Foot Locker on watch after weak Finish Line report https://seekingalpha.com/news/3253295-foot-locker-on-watch-after-weak-finish-line-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3253295-foot-locker-on-watch-after-weak-finish-line-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253284\" data-ts=\"1490356021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UA\" target=\"_blank\">UA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253284-under-armour-races-higher-after-rousing-jefferies-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Under Armour races higher after rousing Jefferies upgrade</a></h4><ul> <li>Jefferies adds Under Armour (<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a>, <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>) to its Franchise Picks List on its <a href=\"https://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Under+Armour,+Inc.+%28UAA%29+to+Buy,+Street+Underappreciates+Growth+Opportunity/12703045.html\" target=\"_blank\">view</a> that valuation is now at an attractive level.</li> <li>The firm's proprietary survey indicates that demand for athletic apparel is quite solid and that the UA brand has strengthened.</li> <li>\"Our revised '18 EPS is 13% above cons., and our webscrapes, store work, and social trend analysis indicate to us an inflection has formed and the buying oppty is now. Our view is compressed valuation and neg. sentiment, ignore compelling growth over the next 2-3 years,\" writes analyst Randal Konik.</li> <li>Konik takes Under Armour to a Buy rating and lifts the price target to $27 from $19.</li> <li>UAA <font color='green'>+4.06%</font> premarket to $19.75. UA <font color='green'>+3.33%</font> to $18.02.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253284\" data-linked=\"Under Armour races higher after rousing Jefferies upgrade\" data-tweet=\"$UA $UA $UAA - Under Armour races higher after rousing Jefferies upgrade https://seekingalpha.com/news/3253284-under-armour-races-higher-after-rousing-jefferies-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3253284-under-armour-races-higher-after-rousing-jefferies-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253282\" data-ts=\"1490355810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253282-micronplus-13-sell-side-lifts-targets-post-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron +13%; sell-side lifts targets post-earnings</a></h4><ul><li><a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">via Notable Calls</a></li><li>Stifel lifts Micron's (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) price target to $47, suggesting&nbsp;<font color='green'>77% upside</font>. the team there thinks overall memory demand could continue to outstrip supply throughout the year.</li><li>Needham outdoes Stifel with a $50 price target. The title of its note: Broad Growth and Content Gains Beats 2014 Cycle.</li><li>UBS's Stephen Chin likens Micron's beat last night to that of Nvidia's (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) last October. He reminds Nvidia&nbsp;<font color='green'>climbed 30%</font>&nbsp;the next day.</li><li>Micron<font color='green'> +13%&nbsp;</font>to $29.91 premarket; <a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>&nbsp;<font color='green'>+3.9%</font>, <a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>&nbsp;<font color='green'>+1.2%</font></li><li>Previously: <a href=\"https://seekingalpha.com/news/3253191-micron-technology-plus-9-percent-q3-2017-outlook-substantial\" target=\"_blank\">Micron Technology +9%; Q3 2017 outlook substantial</a> (March 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253282\" data-linked=\"Micron +13%; sell-side lifts targets post-earnings\" data-tweet=\"$MU $MU $NVDA - Micron +13%; sell-side lifts targets post-earnings https://seekingalpha.com/news/3253282-micronplus-13-sell-side-lifts-targets-post-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3253282-micronplus-13-sell-side-lifts-targets-post-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>72&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253281\" data-ts=\"1490355764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SESN\" target=\"_blank\">SESN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253281-eleven-biotherapeutics-revenues-up-33-in-q4-shares-up-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eleven Biotherapeutics revenues up 33% in Q4; shares up 9% premarket</a></h4><ul><li>Eleven Biotherapeutics (EBIO) <a href=\"https://seekingalpha.com/pr/16780338-eleven-biotherapeutics-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">Q4 results</a>: Revenues: $0.8M (+33.3%); Operating Loss: ($3.6M) (+63.3%); Net Loss: ($3.5M) (+66.0%); Loss Per Share: ($0.15) (+71.7%).</li><li><strong>2016 results</strong>: Revenues: $30M; Operating Income: $2.9M (+108.2%); Net Income: $1.9M (+105.7%); EPS: $0.09 (+105.1%); Quick Assets: $25.3M (-29.9%).</li><li><strong>Financial Guidance</strong>: Eleven expects to have cash to fund R&amp;D programs and operations into early 2018.</li><li>Shares are up&nbsp;<font color='green'>9.5%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253281\" data-linked=\"Eleven Biotherapeutics revenues up 33% in Q4; shares up 9% premarket\" data-tweet=\"$SESN - Eleven Biotherapeutics revenues up 33% in Q4; shares up 9% premarket https://seekingalpha.com/news/3253281-eleven-biotherapeutics-revenues-up-33-in-q4-shares-up-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253281-eleven-biotherapeutics-revenues-up-33-in-q4-shares-up-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253278\" data-ts=\"1490355556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/M\" target=\"_blank\">M</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253278-citi-delivers-harsh-assessment-of-macys\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi delivers harsh assessment of Macy&#39;s</a></h4><ul> <li>Citi is far from sold on the turnaround efforts at Macy's (NYSE:<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a>) after taking in the department store operator's tough start to the year.</li> <li>The firm also points to the large number of retail store closings as an indication that the upside for Macy's real estate transactions could be less than some investors anticipate.</li><li>Shares are downgraded to Neutral from Buy.</li> <li>Source: Bloomberg</li> <li>Macy's <font color='red'>-1.03%</font> premarket to $27.98 vs. a 52-week trading range of $27.83 to $45.41.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253278\" data-linked=\"Citi delivers harsh assessment of Macy&#39;s\" data-tweet=\"$M - Citi delivers harsh assessment of Macy&#39;s https://seekingalpha.com/news/3253278-citi-delivers-harsh-assessment-of-macys?source=tweet\" data-url=\"https://seekingalpha.com/news/3253278-citi-delivers-harsh-assessment-of-macys\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253274\" data-ts=\"1490354796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253274-finish-line-lower-post-fq4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finish Line lower post FQ4 results</a></h4><ul>     <li>Finish Line (NASDAQ:<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a>) reports comparable-store sales fell 4.5% in <a href=\"https://seekingalpha.com/pr/16780357-finish-line-reports-fourth-quarter-full-fiscal-year-2017-results\" target=\"_blank\">FQ4</a>.</li>     <li>Gross margin rate squeezed 500 bps to 29.1%.</li>     <li>SG&amp;A expense rate improved 130 bps to 23.1%.</li>     <li>Adjusted operating margin rate slipped 440 bps to 6%.</li>     <li>Merchandise inventory -4.8% Y/Y to $331.15M.</li>     <li>Store count Y/Y: Finish Line -18 to 573; Branded shops -18 to 374.</li>     <li><b>FY2018 Guidance</b>: Comparable-store sales:&nbsp;increase low-single digits;&nbsp;Adjusted EPS: $1.12 to $1.23.</li><li>FINL&nbsp;<font color='red'>-11.39%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253274\" data-linked=\"Finish Line lower post FQ4 results\" data-tweet=\"$FINL - Finish Line lower post FQ4 results https://seekingalpha.com/news/3253274-finish-line-lower-post-fq4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3253274-finish-line-lower-post-fq4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253271\" data-ts=\"1490354215\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253271-abbott-unloads-44m-shares-of-mylan-40\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abbott unloads 44M shares of Mylan at ~$40</a></h4><ul><li>In a block trade of 44M shares at $39.50 - 40.25, Abbott (NYSE:<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a>) divests 60% of its remaining stake in Mylan NV (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>). The total value of the trade was $1.7B.</li><li>Source: StreetInsider</li><li><strong>Update</strong>: Mylan is down&nbsp;<font color='red'>3%</font>&nbsp;premarket on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253271\" data-linked=\"Abbott unloads 44M shares of Mylan at ~$40\" data-tweet=\"$ABT $ABT $MYL - Abbott unloads 44M shares of Mylan at ~$40 https://seekingalpha.com/news/3253271-abbott-unloads-44m-shares-of-mylan-40?source=tweet\" data-url=\"https://seekingalpha.com/news/3253271-abbott-unloads-44m-shares-of-mylan-40\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253267\" data-ts=\"1490353721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XENE\" target=\"_blank\">XENE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253267-xenon-pharmas-lead-dermatology-candidate-flunks-mid-stage-acne-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xenon Pharma&#39;s lead dermatology candidate flunks mid-stage acne study</a></h4><ul><li>Thinly traded micro cap Xenon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/XENE' title='Xenon Pharmaceuticals'>XENE</a>) is poised for a down day after <a href=\"https://seekingalpha.com/pr/16780321-xenon-pharmaceuticals-announces-xen801-meet-efficacy-endpoints-phase-2-clinical-trial\" target=\"_blank\">announcing</a> that lead dermatology candidate XEN801 failed to beat placebo in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02656043?term=xen801&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> in people with moderate-to-severe acne. Specifically, it failed to demonstrate a statistically valid difference in lesion count from baseline to week 12 compared to placebo. The company will cease development of the candidate for this indication.</li><li><a href=\"https://www.xenon-pharma.com/product-candidates/dermatologic/\" target=\"_blank\">XEN801</a> is a topical stearoyl Co-A desaturase-1 (SCD1) inhibitor.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>35%</font>&nbsp;premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253267\" data-linked=\"Xenon Pharma&#39;s lead dermatology candidate flunks mid-stage acne study\" data-tweet=\"$XENE - Xenon Pharma&#39;s lead dermatology candidate flunks mid-stage acne study https://seekingalpha.com/news/3253267-xenon-pharmas-lead-dermatology-candidate-flunks-mid-stage-acne-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3253267-xenon-pharmas-lead-dermatology-candidate-flunks-mid-stage-acne-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM </div></div></li>","count":48,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}